|Bid||65.08 x 800|
|Ask||80.00 x 1300|
|Day's Range||74.27 - 76.92|
|52 Week Range||22.36 - 93.94|
|Beta (5Y Monthly)||1.90|
|PE Ratio (TTM)||152.56|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In this article we will take a look at the 10 best pharmaceutical stocks to buy according to billionaire Kerr Neilson. You can skip our detailed analysis of the pharmaceutical industry’s outlook for 2021 and some of the major growth catalysts for pharmaceutical stocks and go directly to the 5 Best Pharmaceutical Stocks to Buy […]
In President Joe Biden's first proposed budget to Congress, he requested authorization for spending increases in a number of areas. Specifically, the president proposed a new agency within the National Institutes of Health (NIH) with a directive to cure some of the most pressing diseases of our time, including Alzheimer's disease. If the budget is adopted, biotechs like Denali Therapeutics (NASDAQ: DNLI), Cassava Sciences (NASDAQ: SAVA), and Eli Lilly (NYSE: LLY) could find themselves with more resources than ever in a market that is estimated to reach $13 billion by 2028.